Free Trial
→ Finally… options made simple (From TradeWins) (Ad)tc pixel
NASDAQ:SUPN

Supernus Pharmaceuticals Q3 2026 Earnings Date & Estimates

Supernus Pharmaceuticals logo
$42.67 0.00 (0.00%)
As of 10/9/2026 04:00 PM Eastern

Supernus Pharmaceuticals is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Supernus Pharmaceuticals in Q3 2026

Supernus Pharmaceuticals is expected to post earnings of $0.6150 per share on revenue of $218.29 million. In the same quarter a year earlier Supernus Pharmaceuticals reported $0.46 per share on revenue of $170.00 million. Supernus Pharmaceuticals last reported on August 3, 2026, posting -$1.01 per share and missing the $0.4225 consensus estimate. Supernus Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.6150
Expected Revenue
$218.29 million
Prior-Year EPS
$0.46
Prior-Year Revenue
$170.00 million
Expected EPS Growth
+33.7%
Expected Revenue Growth
+28.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.01 (Missed by -$1.4325)
Last Quarter Revenue
$219.06 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Supernus Pharmaceuticals Q3 2026 Earnings FAQ

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes.

Supernus Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Supernus Pharmaceuticals to post earnings of $0.6150 per share for Q3 2026.

The consensus revenue estimate for Supernus Pharmaceuticals is $218.29 million for Q3 2026.

Supernus Pharmaceuticals Earnings Headlines

Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Zacks Research
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095945
Kiora Pharmaceuticals (NASDAQ:KPRX) vs. Supernus Pharmaceuticals (NASDAQ:SUPN) Critical Comparison
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084233
Finally… options made simple
Ian Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big risks. That belief nearly cost him everything. Now he's sharing the simple, repeatable setup that changed how he approaches trades, no complicated indicators or market-timing required. His free report breaks down the #1 mistake rookie options traders make and a straightforward trade blueprint anyone can follow.tc pixel
October 12 at 1:00 AM  |  TradeWins (Ad)
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
September 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260924109822/en/supernus-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-supernus-pharmaceuticals-inc.---supn/
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
September 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/branded-pharmaceuticals-stocks-q2-results-144840437.html
Why Did Supernus Pharmaceuticals (SUPN) Move Today?
September 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-did-supernus-pharmaceuticals-supn-001950667.html
See More Supernus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Supernus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Supernus Pharmaceuticals and other key companies, straight to your email.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches. Its CNS portfolio also includes Qelbree (viloxazine extended-release), a non-stimulant treatment for ADHD in children and adults. The company has additionally pursued product candidates and commercial opportunities in areas such as Parkinson’s disease and other neurological disorders.

Founded in 2005 and headquartered in Rockville, Maryland, Supernus primarily serves the U.S. pharmaceutical market through its commercial organization and distribution partners. The company was founded and is led by Jack A. Khattar, who serves as president and chief executive officer. Supernus continues to support its commercial products through research, development, and lifecycle-management activities aimed at expanding treatment options in CNS medicine.

View Supernus Pharmaceuticals Profile
Earnings Tools